Introduction
The rates of generalized anxiety disorder (GAD) continue to rise globally. In some cases, patients may not require medications as part of their treatment. However, the diagnosis of GAD often requires prolonged use of anxiolytic drugs. Currently, many types of anxiolytics exist, including benzodiazepines, buspirone, barbiturates, and other alternatives. Each class has its own pharmacokinetics and pharmacodynamics, which must be investigated to determine the best approach for a patient.
Factors of Choice of Anxiolytic
Pharmacokinetics
The pharmacokinetics of anxiolytics refers to how the body interacts with the ingested drug. First-line treatments for anxiety are antidepressants, which are taken orally and have a long half-life and a complex discontinuation syndrome (Rosenthal & Burchum, 2021). Benzodiazepines are considered to be the second primary treatment of GAD in this medication category. They are usually taken orally but can also be administered intravenously, rectally, or by intramuscular injection (Carl et al., 2020).
Additionally, each drug has a unique half-life, which makes it challenging to summarize all drugs as one category. In the case of GAD, benzodiazepines with a long half-life are preferred to taper the symptoms of anxiety (Rosenthal & Burchum, 2021). Here, the half-life may extend to over 40 hours – these medications become active over a slow period of time and convert into other products to prolong their effect.
Pharmacodynamics
When discussing pharmacodynamics, it is essential to consider the central nervous system (CNS). Such drugs as benzodiazepines depress the CNS and raise the levels of gamma-aminobutyric acid (GABA). As an outcome, when used as an anxiolytic, these medications curb the release of serotonin and decrease anxiety (Radosavljevic et al., 2023). Some side effects related to this process come as a result of GABA inhibition. These may include drowsiness, sleepiness, confusion, depression, nausea, and other problems with attention and concentration (Sonmez et al., 2020).
Among antidepressants, selective serotonin reuptake inhibitors (SSRIs) work by limiting the reabsorption of serotonin (Carl et al., 2020). These drugs may also lead to lower emotional responses, suicidal ideation, and sexual dysfunction (Carl et al., 2020). The depression of the CNS causes other consequences and may contribute to one’s cognitive ability and self-control throughout the day.
Some factors exacerbate these outcomes, especially if the drugs are taken inappropriately or abused. For instance, taking anxiolytic drugs of several types, such as benzodiazepines and barbiturates, or taking any other depressants, may exacerbate the effects of the medication. The increased suppression of the CNS can be unsafe for a patient and lead to severe issues, coma, and death (Rosenthal & Burchum, 2021).
Alcohol consumption produces similar effects because it acts as a depressant – it cannot be consumed with most anxiolytic drugs with a long half-life. Thus, the patient’s behavior can significantly affect their health. One’s age is also significant, as children and adolescents are usually not treated with medications other than SSRIs (Rosenthal & Burchum, 2021). Older adults are at a higher risk of complications due to comorbidities, and their treatment options are also limited to SSRIs that do not cause many side effects. There are no specific race or gender-based differences between these drugs that significantly alter their actions.
As noted above, certain antidepressants, such as SSRIs, are chosen as first-line treatment. Their adverse effects are minimal, and they have a low risk of misuse. The next option for GAD is a series of other antidepressants, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). These choices may present with more side effects and are less safe than SSRIs (Sonmez et al., 2020). Finally, some patients who require urgent relief or do not respond to antidepressants can be prescribed benzodiazepines. These medications do not target comorbid depression and have increased risks of sedation.
Conclusion
In conclusion, the selection of anxiolytic drugs is wide and depends on the patient’s specific factors. Most drugs have a long half-life and require slow tapering if the patient wants to change medication. They mainly affect the CNS and can have various side effects, affecting one’s emotional and cognitive responses. Age and behavior are the most influential factors in enhancing the impact of these drugs. Patients are usually prescribed antidepressants or benzodiazepines to treat GAD.
References
Carl, E., Witcraft, S. M., Kauffman, B. Y., Gillespie, E. M., Becker, E. S., Cuijpers, P., Van Ameringen, M., Smits, J. A. J., & Powers, M. B. (2020). Psychological and pharmacological treatments for generalized anxiety disorder (GAD): A meta-analysis of randomized controlled trials. Cognitive Bbehavior Therapy, 49(1), 1-21.
Radosavljevic, M., Svob Strac, D., Jancic, J., & Samardzic, J. (2023). The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. Genes, 14(5), 1095.
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) Elsevier.
Sonmez, A. I., Almorsy, A., Ramsey, L. B., Strawn, J. R., & Croarkin, P. E. (2020). Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations. Depression and Anxiety, 37(8), 747-759.